Newsbenzinga
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
· Published
Article summary
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
An excerpt from the original article.
Comments —
Loading comments…